KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Net (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Receivables - Net for 18 consecutive years, with $5.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Net rose 3.06% year-over-year to $5.7 billion; the TTM value through Mar 2026 reached $5.7 billion, up 3.06%, while the annual FY2025 figure was $5.7 billion, 7.58% down from the prior year.
  • Receivables - Net hit $5.7 billion in Q1 2026 for Regeneron Pharmaceuticals, roughly flat from $5.7 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $6.2 billion in Q4 2024 and bottomed at $4.8 billion in Q1 2022.
  • Average Receivables - Net over 5 years is $5.5 billion, with a median of $5.6 billion recorded in 2023.
  • On a YoY basis, Receivables - Net climbed as much as 15.96% in 2022 and fell as far as 26.25% in 2022.
  • Regeneron Pharmaceuticals' Receivables - Net stood at $5.3 billion in 2022, then rose by 6.35% to $5.7 billion in 2023, then rose by 9.61% to $6.2 billion in 2024, then fell by 7.58% to $5.7 billion in 2025, then fell by 0.18% to $5.7 billion in 2026.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $5.7 billion, $5.7 billion, and $5.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.